44 Wealth Management’s AbbVie ABBV Stock Holding History

44 Wealth Management’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$288K	Sell	1,325 -6	-0.5%	-$1.33K	0.1%	163
2025 Q4	$304K	Buy	+1,331	New	+$303K	0.1%	172
2025 Q3	–	Sell	-1,787	Closed	-$332K	–	201
2025 Q2	$332K	Sell	1,787 -1,028	-37%	-$191K	0.12%	165
2025 Q1	$590K	Sell	2,815 -230	-8%	-$44.7K	0.22%	123
2024 Q4	$541K	Sell	3,045 -58	-2%	-$10.7K	0.21%	126
2024 Q3	$583K	Buy	+3,103	New	+$579K	0.21%	127
2023 Q2	$244K	Sell	1,810 -19	-1%	-$2.79K	0.08%	152
2023 Q1	$291K	Sell	1,829 -83	-4%	-$12.7K	0.1%	146
2022 Q4	$309K	Sell	1,912 -83	-4%	-$12.7K	0.11%	141
2022 Q3	$268K	Buy	1,995 +33	+2%	+$4.74K	0.11%	142
2022 Q2	$300K	Buy	+1,962	New	+$300K	0.12%	137
2021 Q1	–	Sell	-4,075	Closed	-$437K	–	156
2020 Q4	$437K	Buy	+4,075	New	+$392K	0.2%	105

Other funds holding ABBV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

44 Wealth Management's ABBV Position: Q1 2026 in Review

44 Wealth Management reduced its AbbVie (ABBV) stake by 0.45% in Q1 2026, selling an estimated $1.33K and leaving 1,325 shares worth $288K. The position accounts for 0.1% of the portfolio, ranked #163.

44 Wealth Management first reported a position in ABBV in Q4 2020 and has held it in 12 quarters since. The position peaked at $590K in Q1 2025. 4,076 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

44 Wealth Management held 1,325 shares of AbbVie worth $288K as of Q1 2026.
44 Wealth Management sold 6 AbbVie shares in Q1 2026, an estimated $1.33K.
AbbVie made up 0.1% of 44 Wealth Management's portfolio in Q1 2026, its #163 holding.
44 Wealth Management first reported a position in AbbVie in Q4 2020 and has held it in 12 quarters since.
44 Wealth Management's AbbVie position peaked at $590K in Q1 2025.
4,076 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on 44 Wealth Management's 13F filing for Q1 2026, filed 15 May 2026.